A synthetic Novo Nordisk's PYY analogue, PYY1875/NNC0165‐1875 (NN9775‐4708), was examined in combination with semaglutide for obesity treatment but was recently discontinued following the completion of Phase II trials.156, 157. This evidence concerns the gene PYY and Obesity.